Detailed answers about HELIX CLINICAL CONSULTANCY LIMITED, including incorporation, status, business activity, and accounts information.
When was HELIX CLINICAL CONSULTANCY LIMITED founded?
HELIX CLINICAL CONSULTANCY LIMITED was officially incorporated on 1 April 2026 and is registered under company number 17130624. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is HELIX CLINICAL CONSULTANCY LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of HELIX CLINICAL CONSULTANCY LIMITED?
HELIX CLINICAL CONSULTANCY LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does HELIX CLINICAL CONSULTANCY LIMITED do?
HELIX CLINICAL CONSULTANCY LIMITED operates in the following sectors: 70229 - Management consultancy activities other than financial management, 74909 - Other professional, scientific and technical activities n.e.c., 85590 - Other education n.e.c., 86210 - General medical practice activities. These SIC codes provide insight into the company's business activities and industry focus.
What is HELIX CLINICAL CONSULTANCY LIMITED's registered address?
The registered office address of HELIX CLINICAL CONSULTANCY LIMITED is 23 Tabor Road, London, England, W6 0BN. This is the official address filed with Companies House for legal and statutory correspondence.
Is HELIX CLINICAL CONSULTANCY LIMITED financially stable?
Financial accounts for HELIX CLINICAL CONSULTANCY LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.